Intervention and study design
EPI-001 is made from a participant’s own dermal papilla cells. According to the registry, cells are collected, expanded and injected into the scalp. The study combines an initial dose-escalation stage with a placebo-controlled stage.
ClinicalTrials.gov lists the study as Phase I/II, recruiting, with an estimated enrolment of 42. The recorded start date is 12 January 2026 and the estimated study completion is June 2029.
Clinical relevance
Dermal papilla cells help regulate follicle growth. A controlled human study can therefore examine the safety of an expanded autologous cell product and changes in measured hair outcomes. The placebo comparison provides stronger evidence than uncontrolled photographic assessment.
The registered intervention does not involve implantation of newly engineered follicular organs. A positive result would support cell-based follicle rejuvenation but would not establish de novo follicle creation.
Evidence required from the study
Relevant evidence includes recruitment progress, adverse events, predefined hair-count or thickness outcomes, differences from placebo and durability. Registration describes the study plan; conclusions require posted or peer-reviewed results.
Dates and current registry status
The registry was checked again on 1 September 2026. It continued to list the study as recruiting, with an estimated primary completion in June 2028 and estimated study completion in June 2029. These are registry estimates rather than forecasts of approval or commercial availability.